亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A preliminary analysis of integrating thymosin α1 into concurrent chemoradiotherapy and consolidative immunotherapy in unresectable locally advanced non-small cell lung cancer

作者
Hao-Ting Zhang,Fangjie Liu,Daquan Wang,Yi-Xin Xiong,Yuanyuan Zhao,Wenzhuo He,PengXin Zhang,ShiYang Zheng,Bo Xia,Yu Situ,Meng-Ru Wang,Qianwen Liu,Yi Hu,Liangping Xia,Bo Qiu,Hui Liu
出处
期刊:Translational lung cancer research [AME Publishing Company]
卷期号:14 (7): 2710-2722 被引量:4
标识
DOI:10.21037/tlcr-2025-190
摘要

Background: Concurrent chemoradiotherapy (CCRT) followed by consolidative immunotherapy represents the standard of care for unresectable locally advanced non-small cell lung cancer (LA-NSCLC), but critical challenges persist: a considerable number of patients discontinue consolidative immune checkpoint inhibitors (ICIs) due to treatment-related pneumonitis and lymphopenia, while "cold" tumor microenvironments further limit immunotherapy efficacy. Thymosin α1 (Tα1) is a pleiotropic immunomodulator that has been associated with infection prevention and the regulation of immune cells. Thus, we designed this retrospective study to investigate the therapeutic effect of integrating Tα1 into CCRT followed by consolidative immunotherapy in patients diagnosed with unresectable LA-NSCLC. Methods: A retrospective analysis was conducted on a total of 196 patients with unresectable stage IIIA-IIIC LA-NSCLC treated from January 1, 2020, to May 31, 2023. All patients received CCRT (60-64 Gy total irradiation dose, weekly concurrent docetaxel and cisplatin) with or without consolidative nivolumab. According to the use of Tα1, patients were classified into 3 groups: non-Tα1 group, patients who did not receive Tα1; short-term Tα1 group, receipt of Tα1 (1.6 mg) once a week from the beginning of treatment until the end of CCRT; long-term Tα1 group, receipt of Tα1 (1.6 mg) once a week from the beginning of treatment until 12 months post-CCRT. The primary objective was progression-free survival (PFS). The secondary objectives included overall survival (OS), pneumonitis, circulating lymphocyte count and interleukin-6 (IL-6) levels. Pretreatment biopsy samples were collected to evaluate the potential influence of somatic mutations on treatment outcomes. Results: The non-Tα1, short-term Tα1, and long-term Tα1 groups included 48, 101, and 47 patients, respectively. Following CCRT, 77.1%, 75.2%, and 93.6% of patients in the respective groups were eligible for consolidative nivolumab (P=0.03). Median PFS was 14.6 months [95% confidence interval (CI): 11.9-17.3] for the non-Tα1 group, 16.0 months (95% CI: 13.2-18.8) for the short-term Tα1 group, and not reached for the long-term Tα1 group (P=0.03). Median OS was 20.0 months (95% CI: 16.1-23.9) for the non-Tα1 group, 27.6 months (95% CI: 13.8-41.3) for the short-term Tα1 group, and not reached in the long-term Tα1 group (P=0.01). The long-term Tα1 group experienced significantly lower rates of grade ≥2 pneumonitis (35.4% in non-Tα1, 14.5% in long-term Tα1 groups, P=0.02), and lower rates of lymphopenia at 6 months post-CCRT (55.8% in non-Tα1, 30.9% in short-term Tα1, and 22.5% in long-term Tα1 groups, P=0.01). At 2 months post-CCRT, the median IL-6 level in the non-Tα1 group (8.14 pg/mL) was significantly higher than that in the long-term Tα1 group (4.92 pg/mL, P=0.03). Conclusions: Integrating Tα1 into CCRT and consolidative immunotherapy could have a synergistic effect in patients with LA-NSCLC. This combination may enhance survival outcomes and reduce treatment-related toxicity. Further randomized trial is warranted for validation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ttimer发布了新的文献求助10
6秒前
自觉康乃馨完成签到,获得积分10
11秒前
ZYP完成签到,获得积分10
18秒前
受伤若男完成签到,获得积分10
43秒前
45秒前
拉长的映波完成签到,获得积分10
47秒前
yoshi发布了新的文献求助10
51秒前
1分钟前
yoshi完成签到,获得积分10
1分钟前
搜集达人的应助被yoshi采纳,获得10
1分钟前
1分钟前
公冶愚志完成签到 ,获得积分10
1分钟前
1分钟前
失眠晟睿完成签到,获得积分10
1分钟前
平淡的忆梅完成签到,获得积分10
1分钟前
NexusExplorer的应助被飘飘采纳,获得10
2分钟前
烟花的应助被123采纳,获得10
2分钟前
笑点低听枫完成签到,获得积分10
2分钟前
2分钟前
奋斗的石头完成签到 ,获得积分10
2分钟前
机智的觅海完成签到,获得积分10
2分钟前
2分钟前
害羞的乘云完成签到,获得积分10
2分钟前
NeoAir完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
我很好完成签到 ,获得积分10
2分钟前
2分钟前
3分钟前
3分钟前
现代的初之完成签到,获得积分10
3分钟前
合适雨完成签到,获得积分10
3分钟前
3分钟前
elsa622完成签到 ,获得积分10
3分钟前
端庄的如松完成签到,获得积分10
3分钟前
打打的应助被科研通管家采纳,获得10
3分钟前
3分钟前
过时的行云完成签到,获得积分10
3分钟前
3分钟前
柔弱藏花完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179896
求助须知:如何正确求助?哪些是违规求助? 9570103
关于积分的说明 21808343
捐赠科研通 7775692
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557334
邀请新用户注册赠送积分活动 2478881